Genetic Variants in SNCA and the Risk of Sporadic Parkinson’s Disease and Clinical Outcomes: A Review

Table 5

Interactions between alpha-synuclein levels and SNCA SNPs.

Study	SNP	Risk allele	Results
Hu et al. [57]	rs11931074	T	The allele was associated with reduced levels of alpha-synuclein in serum
	REP1		Different alleles and genotypes did not influence levels of alpha-synuclein in serum
Mata et al. [65]	rs356219	C	CC genotype was correlated with increased levels of alpha-synuclein in plasma
Fuchs et al. [84]	rs2583988	T	No correlation with alpha-synuclein mRNA or protein levels
	REP1	261 pb	256 pb/256 bp genotype was associated with lower alpha-synuclein levels assessed in blood samples; no effect in brain samples
	rs356219	C	CT genotype correlated with higher SNCA mRNA levels in the substantia nigra and TT genotype showed higher SNCA mRNA levels in the cerebellum; no effect in blood samples
McCarthy et al. [24]	rs2736990	G	In the 3 SNPs, the GG genotype correlated with an increased expression ratio of SNCA112 mRNA in the frontal cortex
	rs356165	G
	rs356219	G
McCarthy et al. [24]	rs3857059	G	No correlation between genotypes and the ratio expression levels of SNCA112 mRNA
	rs17016074	A
Cardo et al. [39]	rs356165; rs11931074	G; T	No significant differences for the SNCA isoform levels between the different genotypes assessed in brain tissues

Postmortem studies.